Gene · 64783
Papers2,224
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
121 to 140 of 2,224
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The role of m6A methylation genes in predicting poor prognosis in sepsis: identifying key biomarkers and therapeutic targets. | Eur J Med Res | 2024 | 39702336 | PubTator, text mining | PubMed |
| RBM15 increase tumor-infiltrating CD4+ T cell in ESCC via modulating of PLOD3. | Am J Cancer Res | 2024 | 39659928 | PubTator, text mining | PubMed |
| Identification of anoikis-related long non-coding RNA signature as a novel prognostic model in lung adenocarcinoma. | Transl Cancer Res | 2024 | 39525036 | PubTator, text mining | PubMed |
| RBM15 drives the progression of lung adenocarcinoma by regulating N6-methyladenosine-mediated LDHA mRNA stability. | Life Sci | 2024 | 39406308 | PubTator, text mining | PubMed |
| RNA methylase RBM15 facilitates malignant progression of colorectal cancer through regulating E2F2 in an m6A modification-dependent manner. | J Biochem Mol Toxicol | 2024 | 39403943 | PubTator, text mining | PubMed |
| Characterizing m6A modification factors and their interactions in colorectal cancer: implications for tumor subtypes and clinical outcomes. | Discov Oncol | 2024 | 39292326 | PubTator, text mining | PubMed |
| Structures and mechanisms of the RNA m 6A writer. | Acta Biochim Biophys Sin (Shanghai) | 2024 | 39238441 | PubTator, text mining | PubMed |
| RBM15 Promotes High Glucose-Induced Lens Epithelial Cell Injury by Inducing PRNP N6-Methyladenine Modification During Diabetic Cataract. | Curr Eye Res | 2024 | 39206850 | PubTator, text mining | PubMed |
| P53-associated lncRNAs regulate immune functions and RNA-modifiers in gastric cancer. | Heliyon | 2024 | 39166030 | PubTator, text mining | PubMed |
| Identification of RBM15 as a prognostic biomarker in prostate cancer involving the regulation of prognostic m6A-related lncRNAs. | Eur J Med Res | 2024 | 39118157 | PubTator, text mining | PubMed |
| RBM15 activates glycolysis in M1-type macrophages to promote the progression of aortic aneurysm and dissection. | Int J Med Sci | 2024 | 39113895 | PubTator, text mining | PubMed |
| m6A modification of VEGFA mRNA by RBM15/YTHDF2/IGF2BP3 contributes to angiogenesis of hepatocellular carcinoma. | Mol Carcinog | 2024 | 39092767 | PubTator, text mining | PubMed |
| Epigenetic mechanism of RBM15 in affecting cisplatin resistance in laryngeal carcinoma cells by regulating ferroptosis. | Biol Direct | 2024 | 39039611 | PubTator, text mining | PubMed |
| N6-methyladenosine-mediated LINC01087 promotes lung adenocarcinoma progression by regulating miR-514a-3p to upregulate centrosome protein 55. | Kaohsiung J Med Sci | 2024 | 39023191 | PubTator, text mining | PubMed |
| RBM15 Protects From Myocardial Infarction by Stabilizing NAE1. | JACC Basic Transl Sci | 2024 | 38984049 | PubTator, text mining | PubMed |
| Exploring the role of m 6 A writer RBM15 in cancer: a systematic review. | Front Oncol | 2024 | 38915367 | PubTator, text mining | PubMed |
| Identification of m6A modification patterns and RBM15 mediated macrophage phagocytosis in pancreatic cancer: An integrative analysis. | Biochim Biophys Acta Mol Basis Dis | 2024 | 38878830 | PubTator, text mining | PubMed |
| RBM15-Mediated N6-Methyl Adenosine (m6A) Modification of EZH2 Drives the Epithelial-Mesenchymal Transition of Cervical Cancer. | Crit Rev Eukaryot Gene Expr | 2024 | 38842201 | PubTator, text mining | PubMed |
| RBM15 facilities lung adenocarcinoma cell progression by regulating RASSF8 stability through N6 Methyladenosine modification. | Transl Oncol | 2024 | 38838436 | PubTator, text mining | PubMed |
| The m6A writer RBM15 drives the growth of triple-negative breast cancer cells through the stimulation of serine and glycine metabolism. | Exp Mol Med | 2024 | 38825643 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/64783/papers?page=7